Logo image
Dystrophinopathy muscle biopsies in the genetic testing ERA: One center's data
Journal article   Peer reviewed

Dystrophinopathy muscle biopsies in the genetic testing ERA: One center's data

Courtney R Carlson, Steven A Moore and Katherine D Mathews
Muscle & nerve, Vol.58(1), pp.149-153
01/24/2018
DOI: 10.1002/mus.26083
PMCID: PMC6057846
PMID: 29365344

View Online

Abstract

Comprehensive genetic testing for dystrophinopathy can detect ∼95% of pathogenic variants in the dystrophin gene (DMD) and is often the preferred diagnostic approach. We reviewed pathology reports for muscle biopsies evaluated at the University of Iowa with a pathological diagnosis of dystrophinopathy based on dystrophic histopathology and abnormal immunofluorescence staining: reduced to absent dystrophin, expression of utrophin, and loss of neuronal nitric oxide synthase. The percentage of muscle biopsies with dystrophinopathy has been stable since 1997. Among 2,298 biopsies evaluated between 2011 and 2016, 72 (3.1%) had pathologic features of dystrophinopathy. Median age at biopsy was 8 years (range, 0.66-84). Half had undergone DMD genetic testing prior to biopsy. Clinical phenotypes recorded on requisitions were typical of muscular dystrophy for 57 (79%) biopsies. Muscle biopsy continues to play an important role in the diagnosis of dystrophinopathy, particularly in patients with later symptom onset, comorbidities, or normal DMD genetic testing results. Muscle Nerve, 2018.
Duchenne-Becker muscular dystrophy diagnosis dystrophinopathy pathology indication muscle biopsy

Details

Metrics

Logo image